Skip to content

Treatment of Verruca Plana by external application of tubeimoside injection: a randomized, double-blind, placebo-controlled, multicenter clinical trial.

A randomized, double-blind, placebo-controlled, multicenter clinical trial of tubeimoside injection for external use in the treatment of Verruca Plana

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000033533
Enrollment
Unknown
Registered
2020-06-04
Start date
2020-06-01
Completion date
Unknown
Last updated
2020-06-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Flat Wart

Interventions

Sponsors

Shaanxi Provincial Hospital of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Patients who meet the diagnostic criteria of Western medicine for verruca plana; 2. Patients aged 18-65 years; 3. Patients with skin lesions on trunk and limbs; 4. Patients who have not used the internal medicine related to this disease, such as vitamin A acid and interferon, have not used the external medicine related to this disease within 30 days before treatment; 5. For the patients without contraindications in this study; 6. Patients signing informed consent.

Exclusion criteria

Exclusion criteria: 1. The patients whose skin rash has obviously fused into pieces; 2. Pregnant and lactating women; 3. Patients with scar constitution and allergic constitution; 4. Patients with serious primary diseases such as heart, brain, liver, kidney, hematopoietic system, endocrine system, etc., in which alt, AST > 1.5 times of the upper limit of normal value, Cr, bun > 1.2 times of the normal value; 5. Patients with neurological and mental disorders who are unable to cooperate, and those who suspect or have a history of alcohol and drug abuse; 6. Patients with HIV infection, tumor and low immunity; 7. Patients with interruption during treatment; 8. Patients who participated in other clinical trials in the past month.

Design outcomes

Primary

MeasureTime frame
Curative Effect of disease;

Secondary

MeasureTime frame
Quality of life scale for dermatosis;

Countries

China

Contacts

Public ContactXiaoning Yan

Shaanxi Provincial Hospital of Traditional Chinese Medicine

xny_sxtcm@126.com+86 15529291985

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026